CEO, Blueprint Medicines
Kate Haviland brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, portfolio strategy, investor relations and commercial execution. Since April 2022, Ms. Haviland has served as Chief Executive Officer of Blueprint Medicines. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Over this time, she was the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in biochemistry/molecular biology and economics and an M.B.A. from Harvard Business School. Kate currently serves on the Board of Directors of Bicara Therapeutics, a private clinical-stage biotechnology company that develops therapies for treating cancer, and she serves as Chair of the Board of Directors of Fulcrum Therapeutics and is a member of the Audit and Nomination and Corporate Governance Committees.